Both studies were reported at the Society of Gynecologic Oncology (SGO) annual meeting in Seattle. "Clearly, this was a definitive negative trial for the overall population," said Thomas J.

Thus, "there is no survival benefit in terms of recurrence-free survival and overall survival," Ryu said in a presentation at the Society of Gynecologic Oncology (SGO) annual meeting in Seattle.

"Caris and our POA collaborators are proud to present five studies at this year's SGO Annual Meeting highlighting the critical role of molecular profiling and biomarkers in personalizing treatment ...

Moore, MD, discusses the exciting advancements in endometrial cancer treatment, particularly over the past 2 years, as she prepares for the 2025 Society of Gynecologic Oncology Annual Meeting on ...

will collectively present five studies across multiple gynecological tumor types at the Society of Gynecologic Oncology's (SGO) Annual Meeting on Women's Cancer, March 14-17, 2025, in Seattle ...

Poster and abstract summaries highlighting this research will be available onsite at Caris' booth #416. The full abstracts will be available on the Caris website following the presentation. The ...

"Caris and our POA collaborators are proud to present five studies at this year's SGO Annual Meeting highlighting the critical role of molecular profiling and biomarkers in personalizing treatment for ...